X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/09/2859845/0/en/ProMIS-Neurosciences-Publishes-in-the-Journal-of-Biological-Chemistry-on-the-Interaction-Between-Pathogenic-Proteins-as-a-Treatment-Target-for-ALS.html
https://www.globenewswire.com/news-release/2024/04/04/2857640/0/en/ProMIS-Neurosciences-to-Present-in-Upcoming-Investor-Conferences-in-April.html
https://www.globenewswire.com/news-release/2024/04/01/2855463/0/en/ProMIS-Neurosciences-Announces-Full-Year-2023-Financial-Results-and-Recent-Highlights.html
https://www.globenewswire.com//news-release/2024/03/11/2843613/0/en/ProMIS-Neurosciences-Strengthens-Global-Intellectual-Property-Portfolio.html
https://www.globenewswire.com//news-release/2024/02/22/2833510/0/en/ProMIS-Neurosciences-to-Present-at-the-2024-BIO-CEO-Investor-Conference.html
https://www.globenewswire.com//news-release/2024/01/22/2812897/0/en/ProMIS-Neurosciences-Achieves-Milestone-in-Development-of-Therapeutic-Alpha-Synuclein-Vaccine.html
https://www.globenewswire.com//news-release/2024/01/08/2805275/0/en/ProMIS-Neurosciences-Issues-Letter-to-Shareholders.html
https://www.globenewswire.com//news-release/2023/12/20/2799157/0/en/ProMIS-Neurosciences-Announces-Publication-on-Novel-Target-for-ALS.html
https://www.globenewswire.com/news-release/2023/11/20/2783119/0/en/ProMIS-Neurosciences-Doses-First-Subjects-in-Phase-1a-Clinical-Trial-of-PMN310-to-Treat-Alzheimer-s-Disease.html
https://www.globenewswire.com//news-release/2023/11/14/2780572/0/en/ProMIS-Neurosciences-Announces-Third-Quarter-2023-Financial-Results-and-Recent-Highlights.html
Market Place
Share 
